今日，先博生物宣布，其自主研发的通用型异体CD19 CAR-NK药物SNC103已成功完成两例一期临床给药，该疗法针对复发和/或难治性 ...

科济药业-B（02171）早盘持续走高，股价上涨9.62%，现报10.14港元，成交额7102.37万港元。 科济药业今早宣布，公司自主研发的 ...

Preclinical studies using transgenic mice expressing human CD19 have shown that pre-B cells and their malignant counterparts, as well as pre-existing antibody-producing and autoantibody-producing ...

In CAR-T therapy, CD19 is now the most extensively used target. It has been confirmed to be effective and safe for the treatment of CLL, B-ALL and B cell lymphoma. FMC63, an IgG2a mouse monoclonal ...

Furie et al. now report favorable results for their phase I trial of belimumab—a fully human, neutralizing, monoclonal antibody against B-lymphocyte stimulator—which both stimulates ...

CD19, a B-cell surface protein, is expressed across B-cell development and it is expressed on almost all B-cell malignancies, such as ALL, chronic lymphocytic leukemia (CLL) and several non ...